Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
2026-06-30T20:35:21.000Z - 3 minutes ago
Jun 30, 2026, 4:30 PM EDT - 9 minutes ago
2026-06-24T10:05:11.000Z - 6 days ago
Jun 3, 2026, 8:30 AM EDT - 27 days ago
2026-05-22T09:50:47.000Z - 5 weeks ago
May 21, 2026, 8:28 PM EDT - 5 weeks ago
2026-03-17T12:16:31.000Z - 3 months ago
Mar 17, 2026, 8:08 AM EDT - 3 months ago
2026-02-17T13:55:30.000Z - 4 months ago
Feb 17, 2026, 8:44 AM EST - 4 months ago
2026-02-11T11:16:00.000Z - 4 months ago
Oct 30, 2025, 10:04 AM EDT - 8 months ago
2025-08-04T17:30:33.000Z - 11 months ago
2025-08-04T17:25:16.000Z - 11 months ago
2025-07-28T11:35:07.000Z - 1 year ago
Jul 28, 2025, 7:30 AM EDT - 1 year ago
2025-07-25T12:40:53.000Z - 1 year ago
Jul 25, 2025, 8:31 AM EDT - 1 year ago
2025-07-24T12:51:27.000Z - 1 year ago
Jul 24, 2025, 8:31 AM EDT - 1 year ago
2025-07-22T17:45:39.000Z - 1 year ago
2025-07-22T17:35:35.000Z - 1 year ago
2025-07-22T17:35:29.000Z - 1 year ago
Jul 22, 2025, 1:30 PM EDT - 1 year ago
2025-06-30T14:47:52.000Z - 1 year ago
2025-06-30T14:47:46.000Z - 1 year ago
2025-06-25T18:00:26.000Z - 1 year ago
2025-06-25T17:55:16.000Z - 1 year ago
2025-06-24T20:55:20.000Z - 1 year ago
2025-06-24T20:55:09.000Z - 1 year ago